MX362237B - Conjugado de un fotosensibilizador y quitosan y usos de los mismos. - Google Patents

Conjugado de un fotosensibilizador y quitosan y usos de los mismos.

Info

Publication number
MX362237B
MX362237B MX2014013516A MX2014013516A MX362237B MX 362237 B MX362237 B MX 362237B MX 2014013516 A MX2014013516 A MX 2014013516A MX 2014013516 A MX2014013516 A MX 2014013516A MX 362237 B MX362237 B MX 362237B
Authority
MX
Mexico
Prior art keywords
chitosan
photosensitiser
conjugate
relates
novel
Prior art date
Application number
MX2014013516A
Other languages
English (en)
Other versions
MX2014013516A (es
Inventor
Berg Kristian
Høgset Anders
Másson Már
S Gaware Vivek
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pci Biotech As filed Critical Pci Biotech As
Publication of MX2014013516A publication Critical patent/MX2014013516A/es
Publication of MX362237B publication Critical patent/MX362237B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a conjugados a base de quitosán novedosos, por ejemplo, nanoportadores, que comprende un derivado del quitosán de polímero biocompatible conjugado a un agente fotosensibilizante, y usos del mismo en la internalización fotoquímica (PCI) y terapia fotodinámica (PDT). La invención también se refiere al uso de los conjugados novedosos de la invención en el tratamiento o prevención de enfermedades, particularmente cáncer, y para propósitos de vacunación.
MX2014013516A 2012-05-15 2013-05-14 Conjugado de un fotosensibilizador y quitosan y usos de los mismos. MX362237B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1208548.6A GB201208548D0 (en) 2012-05-15 2012-05-15 Compound and method
PCT/EP2013/059968 WO2013189663A1 (en) 2012-05-15 2013-05-14 Conjugate of a photosensitiser and chitosan and uses thereof

Publications (2)

Publication Number Publication Date
MX2014013516A MX2014013516A (es) 2015-11-13
MX362237B true MX362237B (es) 2019-01-09

Family

ID=46458880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013516A MX362237B (es) 2012-05-15 2013-05-14 Conjugado de un fotosensibilizador y quitosan y usos de los mismos.

Country Status (24)

Country Link
US (1) US9901636B2 (es)
EP (1) EP2849791B1 (es)
JP (1) JP6456284B2 (es)
KR (2) KR20150013803A (es)
CN (1) CN104780941B (es)
AU (1) AU2013279748B2 (es)
BR (1) BR112014028315B1 (es)
CA (1) CA2873259C (es)
DK (1) DK2849791T3 (es)
ES (1) ES2682762T3 (es)
GB (1) GB201208548D0 (es)
HK (1) HK1203850A1 (es)
HR (1) HRP20181276T1 (es)
HU (1) HUE039725T2 (es)
IN (1) IN2014DN09418A (es)
MX (1) MX362237B (es)
NZ (1) NZ630582A (es)
PL (1) PL2849791T3 (es)
PT (1) PT2849791T (es)
RU (1) RU2675830C2 (es)
SG (1) SG11201407603YA (es)
SI (1) SI2849791T1 (es)
WO (1) WO2013189663A1 (es)
ZA (1) ZA201408406B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US10973896B2 (en) 2014-04-11 2021-04-13 Pci Biotech As Treatment or prevention of melanoma using photochemical internalization of a melanoma antigen
CA2959207A1 (en) 2014-08-28 2016-03-03 Pci Biotech As Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine
CN104650259A (zh) * 2015-01-23 2015-05-27 广西大学 一种纳米孔壳聚糖四(4-磺酸基苯基)金属卟啉微球及其制备方法和使用方法
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
GB201511159D0 (en) 2015-06-24 2015-08-05 Univ Nottingham Controlled cell delivery vehicle and treatment of tumours
JP6776364B2 (ja) * 2016-03-22 2020-10-28 オーボ アカデミー ユニヴァーシティー 蛍光増白剤としての多糖誘導体
KR20190013289A (ko) * 2017-08-01 2019-02-11 순천대학교 산학협력단 수용성 키토산을 포함하는 나노광증감제
GB201801169D0 (en) * 2018-01-24 2018-03-07 Pci Biotech As Method
CN108892743A (zh) * 2018-05-28 2018-11-27 南京工业大学 用于光动力抗菌的纳米光敏剂，其制备方法及应用
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
CN115399328B (zh) * 2021-05-27 2024-03-22 中国科学院化学研究所 一种多糖基杀菌材料及其制备方法和应用
GB202115451D0 (en) 2021-10-27 2021-12-08 Pci Biotech As Method
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) * 1999-03-15 1999-05-05 Photocure As Method
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
JP2002241307A (ja) * 2001-02-19 2002-08-28 Yasuhiko Tabata 光増感剤を含有する超音波治療用活性酸素発生剤
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
GB0415663D0 (en) * 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound
US20090209508A1 (en) 2005-05-16 2009-08-20 Universite De Geneve Compounds for Photochemotherapy
JP4287411B2 (ja) * 2005-07-01 2009-07-01 株式会社東芝 仮想メモリシステムおよび仮想記憶方法
CN101024087A (zh) * 2007-03-28 2007-08-29 长沙理工大学 壳聚糖－多肽－卟啉纳米药物载体及其制备和应用
KR101035269B1 (ko) * 2007-04-23 2011-05-26 한국과학기술연구원 고분자 유도체-광감작제 복합체를 이용한 새로운 광역학치료제
KR20090047872A (ko) 2007-11-08 2009-05-13 인제대학교 산학협력단 신규 카보하이드레이트 복합 클로린 화합물 및 이의제조방법
WO2009077908A1 (en) 2007-12-14 2009-06-25 University Of Lausanne Colloidal particle comprising multivalent cyclic anions
KR101076717B1 (ko) 2008-11-07 2011-10-26 재단법인대구경북과학기술원 광역학 치료용 나노구조체 및 그 제조방법
US20100129432A1 (en) 2008-11-25 2010-05-27 Taipei Medical University Microorganism-killing combination
KR100918811B1 (ko) 2009-04-29 2009-09-25 다이아텍코리아 주식회사 클로린 ｅ６-엽산 결합 화합물 및 키토산을 함유하는 암 치료용 약학적 조성물
CN101977608A (zh) 2009-04-29 2011-02-16 多异亚德韩国株式会社 含有二氢卟酚e6-叶酸共轭化合物和壳聚糖的用于癌症治疗的药物组合物
CN102573910B (zh) * 2009-06-12 2015-08-26 鹿特丹伊拉斯谟大学医疗中心 用于癌症光动力学治疗的靶向纳米光药物
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
KR101228106B1 (ko) 2010-01-21 2013-02-01 광주과학기술원 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체
KR101250150B1 (ko) * 2010-10-29 2013-04-04 가톨릭대학교 산학협력단 광역학치료를 위한 고분자-광응답제 접합체 및 이의 제조방법

Also Published As

Publication number Publication date
RU2014150569A (ru) 2016-07-10
US20150202293A1 (en) 2015-07-23
SG11201407603YA (en) 2014-12-30
EP2849791A1 (en) 2015-03-25
WO2013189663A1 (en) 2013-12-27
BR112014028315B1 (pt) 2022-02-22
CA2873259A1 (en) 2013-12-27
BR112014028315A2 (pt) 2017-10-24
AU2013279748B2 (en) 2018-08-02
PL2849791T3 (pl) 2019-03-29
KR20150013803A (ko) 2015-02-05
ES2682762T3 (es) 2018-09-21
HK1203850A1 (en) 2015-11-06
DK2849791T3 (en) 2018-08-13
KR102269861B1 (ko) 2021-06-28
ZA201408406B (en) 2016-02-24
KR20200085380A (ko) 2020-07-14
HUE039725T2 (hu) 2019-01-28
AU2013279748A1 (en) 2014-11-20
NZ630582A (en) 2017-02-24
RU2675830C2 (ru) 2018-12-25
US9901636B2 (en) 2018-02-27
MX2014013516A (es) 2015-11-13
IN2014DN09418A (es) 2015-07-17
SI2849791T1 (sl) 2018-10-30
PT2849791T (pt) 2018-10-04
CN104780941A (zh) 2015-07-15
JP6456284B2 (ja) 2019-01-23
EP2849791B1 (en) 2018-07-04
GB201208548D0 (en) 2012-06-27
HRP20181276T1 (hr) 2018-11-16
CN104780941B (zh) 2019-01-15
CA2873259C (en) 2021-08-03
JP2015516496A (ja) 2015-06-11

Similar Documents

Publication Publication Date Title
MX2014013516A (es) Conjugado de un fotosensibilizador y quitosan y usos de los mismos.
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
MX360098B (es) Conjugados dirigidos encapsulados en partículas y sus formulaciones.
EP4140487A8 (en) Combination therapy for treating cancer
WO2012045090A3 (en) Therapeutic use of a tlr agonist and combination therapy
EA033456B1 (ru) Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры
EP2949344A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
EA201491711A1 (ru) Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
MX369664B (es) Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer.
MX2024008222A (es) Hidrogeles de acido hialuronico degradables.
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
WO2010151074A3 (ko) 양자점-클로린 유도체의 접합체를 함유하는 광감작제 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료 및 진단용 조성물
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
MX2021003186A (es) Nuevos conjugados de hidrogel.
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX2018002932A (es) Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer.
EP2424536A4 (en) NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION
MX2018012392A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
WO2013052158A3 (en) Targeted nanovectors and their use for treatment of brain tumors
EP2566856A4 (en) COMPOUNDS AND METHODS FOR TREATING CEREBRAL DISORDERS
CY1116088T1 (el) Δοκοζαεξανοϊκος πανθενυλεστερας και χρηση αυτου για θεραπεια και αποτροπη καρδιαγγειακων ασθενειων
BR112014013561A2 (pt) composição farmacêutica útil para o tratamento de um câncer, tumor maligno, tumor benigno e doenças não-malignas, composição útil para a preparação de uma composição farmacêutica, método para o tratamento de um tumor em um paciente, e, método para o tratamento de uma condição da pele de um paciente
MX2012006217A (es) Derivados de peroxido nuevos, su proceso de preparacion y su uso en medicina humana y en cosmeticos para el tratamiento o prevencion de acne.
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates

Legal Events

Date Code Title Description
FG Grant or registration